Janux Therapeutics
Developing unique immunotherapies that generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. Learn more
Launch date
Employees
Market cap
€2.4b
Enterprise valuation
€1.8b (Public information from Sep 2024)
Share price
$49.98 JANX
San Diego California (HQ)
Authorizing premium user...